Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

fluorouracil topical (Rx)Brand and Other Names:Efudex, Carac, more...Fluoroplex, Tolak

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

cream

  • 0.5% (Carac)
  • 1% (Fluoroplex)
  • 4% (Tolak)
  • 5% (Efudex)

topical solution

  • 2% (Efudex)
  • 5% (Efudex)
more...

Actinic (Solar) Keratoses

Carac: Apply thin film to affected area qDay for 2-4 wk; healing may not be evident for 1-2 months

Efudex (2% solution): Apply sufficient amount to cover lesions q12hr for 2-4 wk; healing may not be evident for 1-2 months

Fluoroplex: Apply sufficient amount to cover lesions q12hr for 2-6 wk

Tolak (face, ears, or scalp): Apply sufficient amount to cover lesions of affected area(s) qDay for 4 weeks

Superficial Basal Cell Carcinoma

Efudex 5%: Apply sufficient amount of cream or solution to cover lesions q12hr for 3-6 wk; may continue application for up to 10-12 weeks

Not recommended

Next

Adverse Effects

Frequency Not Defined

Pain

Pruritus

Headache

Insomnia

Irritability

Rash

Photosensitivity

Leukocytosis

Thrombocytopenia

Birth defects

Burning

Inflammation

Miscarriage

Herpes simplex

Allergic contact dermatits

Telangectasia

Hyperpigmentation (rare)

Scarring (rare)

Previous
Next

Warnings

Contraindications

Hypersensitivity to any component

Women who are or may become pregnant

Dihydropyrimidine Dehydrogenase (DPD) deficiency

Cautions

Potential for delayed hypersensitivity reaction to fluorouracil

Occlusive dressings may increase inflammatory reaction in adjacent normal skin

Possibility for increased absorption through inflamed or ulcerated skin

Avoid prolonged exposure to sunlight or other UV irradiation

Superficial BCC treatment only when conventional methods are impractical, since conventional methods have better response rate

Previous
Next

Pregnancy & Lactation

Pregnancy Category: X

Lactation: Unknown; not recommended

Pregnancy Categories

A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA:Information not available.

more...
Previous
Next

Pharmacology

Mechanism of Action

Interferes with synthesis of DNA & to a lesser extent, RNA

Pharmacokinetics

Absorption: Insignificant (~6%)

Time to peak: 1 hr

Previous
Next

Administration

Topical Administration

Apply q12hr with nonmetallic applicator, gloved hands or fingertips

If fingertips used, wash hands immediately afterwards

Solution considered more effective than cream for equivalent strength

Complete healing of lesions typically not evident for 1-2 months

Previous
Next

Images

Previous
Next

Formulary

FormularyPatient Discounts

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Add or Remove Plans
Plans for
Select State:
Non-Medicare PlansMedicare Plans

Select a box to add or remove a plan.

Select a class to view formulary status for similar drugs

Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.